Last update: July 31, 2018

Papaverine

Low Risk for breastfeeding


Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.

An alkaloid derived from the opium of the Papaver somniferum plant or prepared synthetically. Not structurally related to the rest of opium alkaloids such as morphine or codeine.
It has a relaxant effect on the vascular system, bronchial musculature and the gastrointestinal, biliary and urinary tracts (American Regent 2017).
Indicated in coronary, pulmonary, peripheral or cerebral vascular spasms and gastrointestinal, ureteral or biliary colic. Oral, intramuscular or intravenous administration every 3 to 12 hours.

Since the last update we have not found published data on its excretion in breastmilk.

Its pharmacokinetic data (large volume of distribution, high percentage of protein binding, short half-life, pKa acid) make transfer to milk in significant quantities unlikely.

Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity.

Alternatives

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Papaverine is also known as


Papaverine in other languages or writings:

Tradenames

Main tradenames from several countries containing Papaverine in its composition:

  • Antipasmol™. Contains other elements than Papaverine in its composition
  • Atroveran Composto™. Contains other elements than Papaverine in its composition
  • Bo Wei (泊威)
  • Buton™. Contains other elements than Papaverine in its composition
  • Colicor™. Contains other elements than Papaverine in its composition
  • Dipatropin™. Contains other elements than Papaverine in its composition
  • Dolospam™. Contains other elements than Papaverine in its composition
  • Fei Lin (菲林)
  • Mesotina

Pharmacokinetics

Variable Value Unit
Bioavailability 28 (5 - 99) %
Molecular weight 339 daltons
Protein Binding 90 - 95 %
VD 3,1 l/Kg
pKa 6,03 -
Tmax 2,5 hours
T1/2 0,5 - 2, 2 hours

References

  1. American Regent. Papaverine. Drug Summary. 2017 Full text (in our servers)
  2. AcoFarma. Papaverina. Ficha técnica. 2010 Full text (in our servers)
  3. Berg G, Jönsson KA, Hammar M, Norlander B. Variable bioavailability of papaverine. Pharmacol Toxicol. 1988 Abstract
  4. Wilén G, Ylitalo P. Metabolism of [14C] papaverine in man. J Pharm Pharmacol. 1982 Abstract Full text (link to original source)
  5. Garrett ER, Roseboom H, Green JR Jr, Schuermann W. Pharmacokinetics of papaverine hydrochloride and the biopharmaceutics of its oral dosage forms. Int J Clin Pharmacol Biopharm. 1978 Abstract
  6. Ritschel WA, Hammer GV. Pharmacokinetics of papaverine in man. Int J Clin Pharmacol Biopharm. 1977 Abstract

Total visits

4,178

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by El Parto Es Nuestro from Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM